Evan David Seigerman
Stock Analyst at BMO Capital
(0.99)
# 1715
Out of 5,270 analysts
42
Total ratings
34.38%
Success rate
16.70%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Merck & Co | Maintains: Market Perform | 105 96 | 92.7 | 3.56% | 4 | Feb 5, 2025 | |
AbbVie | Maintains: Outperform | 208 215 | 211.25 | 1.78% | 7 | Feb 3, 2025 | |
Replimune Group | Maintains: Outperform | 18 27 | 12.11 | 122.96% | 3 | Jan 22, 2025 | |
Novo Nordisk | Maintains: Outperform | 156 105 | 89.93 | 16.76% | 5 | Dec 23, 2024 | |
Regeneron Pharmaceut... | Maintains: Outperform | 1300 1190 | 687.82 | 73.01% | 5 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 52 57 | n/a | n/a | 3 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 83 100 | 22.88 | 337.06% | 2 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 336 355 | 309.49 | 14.7% | 3 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Outperform | 33 36 | 26.02 | 38.36% | 4 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 31 72 | n/a | n/a | 4 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 9 3 | 8.12 | -63.05% | 1 | May 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 369 396 | 927.19 | -57.29% | 1 | Sep 6, 2022 |